Core Insights - The biotech industry is characterized by high risks and potential rewards, where positive news can significantly impact share prices and company viability [1] Group 1: Boston Scientific - Boston Scientific Corp. specializes in medical devices for gastrointestinal and pulmonary conditions, with recent FDA safety alerts affecting its heart devices leading to a temporary dip in share price [2][3] - The company reported a 17% year-over-year (YOY) organic sales increase, with a notable 28% growth for its Watchman device, surpassing analyst expectations for both revenue and earnings [4][5] - Analysts are bullish on Boston Scientific, with 24 out of 26 rating it a Buy and a price target suggesting over 10% upside potential [5] Group 2: Arcutis Biotherapeutics - Arcutis Biotherapeutics focuses on dermatological treatments, with its product ZORYVE driving a remarkable 164% YOY growth in product sales for the latest quarter [6][7] - The FDA approved ZORYVE foam for additional uses, expanding its market reach, and the company anticipates further regulatory decisions later in the year [7][8] - Despite facing competition, Arcutis has a strong pipeline and is rated a Buy by six out of seven analysts, with a potential upside of 24% [8] Group 3: Tarsus Pharmaceuticals - Tarsus Pharmaceuticals specializes in eye care, reporting a net sales beat of nearly $103 million, driven by its Demodex treatment XDEMVY [10][11] - The company is conducting a promising Phase II study for its TP-04 treatment for ocular rosacea, contributing to a positive outlook among analysts [11] - Tarsus shares have increased about 4% year-to-date, with analysts indicating over 16% upside potential [11]

Second Quarter 2025 Financial Results Conference Call August 6, 2025 Matt, an XDEMVY® Patient Today's Speakers Bobby Azamian, MD, PhD CEO & Chairman Aziz Mottiwala Chief Commercial Officer Jeff Farrow Chief Financial & Strategy Officer 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. These statements and the most recent Form 10-Q quarterly filing filed with the SEC include statemen ...

Core Insights - Tarsus Pharmaceuticals reported record quarterly net product sales of $102.7 million for Q2 2025, marking a 152% increase year over year, driven by the successful launch of XDEMVY [1][5] - The Direct-To-Consumer campaign has significantly increased patient engagement and prescriptions, with active consumer engagement on the XDEMVY website up nearly 400% since the start of 2025 [5] - The company is on track with its pipeline advancements and global expansion efforts, including plans for regulatory meetings in Japan and potential European approval for a preservative-free formulation of XDEMVY [5][10] Recent Business and Clinical Highlights - XDEMVY has established itself as the standard of care for Demodex blepharitis, with over 91,000 bottles distributed in Q2 2025 [2][5] - More than 20,000 Eye Care Professionals (ECPs) are now prescribing XDEMVY, a 30% increase since the beginning of 2025 [5] - The company plans to initiate a Phase 2 study of TP-04 for ocular rosacea in H2 2025 and a Phase 2 study of TP-05 for Lyme disease prevention in 2026 [5] Financial Results - For Q2 2025, product sales were $102.7 million compared to $40.8 million in Q2 2024, with a total of approximately 91,000 bottles delivered [5][10] - Cost of sales increased to $6.2 million from $3.0 million in the same period last year, primarily due to manufacturing costs related to XDEMVY [10] - Research and development expenses rose to $15.6 million from $12.3 million in Q2 2024, driven by increased program expenses and personnel-related costs [6][10] Year-to-Date Financial Performance - Year-to-date product sales reached $181.0 million, up from $65.5 million in the same period in 2024 [10] - Selling, general and administrative expenses increased to $188.0 million from $110.4 million, largely due to higher commercial and marketing costs associated with the XDEMVY launch [10] - The net loss for the year-to-date period was $45.5 million, an improvement from a net loss of $69.0 million in the same period in 2024 [10]

Core Insights - Tarsus Pharmaceuticals reported a significant increase in net product sales of XDEMVY, reaching $78.3 million, which represents a 217% year-over-year growth and an 18% increase over Q4 2024 [4][10] - The company has strengthened its financial position by raising approximately $135 million through a public equity offering, resulting in cash, cash equivalents, and marketable securities totaling approximately $408 million as of March 31, 2025 [4][10] - Tarsus is on track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the treatment of Ocular Rosacea in the second half of 2025 [4][10] Financial Performance - The first quarter of 2025 saw net product sales of XDEMVY at $78.3 million compared to $24.7 million in the same period of 2024, driven by approximately 72,000 bottles delivered to patients, up from 26,000 bottles year-over-year [10][19] - Cost of sales increased to $5.2 million from $1.7 million in the prior year, attributed to manufacturing costs and royalties [10][19] - Research and development expenses rose to $14.4 million from $12.1 million, while selling, general, and administrative expenses increased to $85.0 million from $51.6 million, primarily due to higher payroll and marketing costs [10][19] - The net loss for the quarter was $25.1 million, an improvement from a net loss of $35.7 million in the same quarter of 2024, with a basic and diluted net loss per share of $(0.64) compared to $(1.01) [10][19] Business Highlights - XDEMVY is positioned to be one of the fastest-growing anterior segment medicines, with broad commercial reimbursement coverage extending to over 90% of covered lives [4][10] - The company reported a gross-to-net discount of approximately 47% and a 23% increase in the number of bottles dispensed compared to Q4 2024 [4][10] - Direct-to-consumer advertising led to a 140% increase in average weekly website visits in March 2025 compared to December 2024 [4][10] - Tarsus is advancing its pipeline with multiple catalysts expected in 2025, including a meeting with regulatory authorities in Japan to discuss the regulatory path for XDEMVY [4][10] Pipeline Developments - Tarsus is on track to initiate a Phase 2 study of TP-04 for Ocular Rosacea, a condition with no FDA-approved therapy, in H2 2025 [4][10] - The company is also developing TP-05, an investigational oral tablet for the potential prevention of Lyme disease, expected to begin trials in 2026 [5][10]